Table 1.
Eligibility criteria based on the PECo strategy.
Table 2.
Risk of bias assessment.
Fig 1.
PRISMA flow diagram.
Fig 2.
Trend of publications.
Table 3.
Types of CADD methods used and the study context.
Table 4.
Summary of different docking tools used in the studies.
Table 5.
Molecular dynamic simulation software used.
Table 6.
Online ligand databases used.
Fig 3.
Chemical structure depiction of the hit compounds.
Table 7.
Target proteins and anticancer properties of anthraquinone derivatives elucidated by CADD methods.
Fig 4.
Targets involved that tackled the hallmarks of cancer.
Fig 5.
Risk of bias assessment outcome.